

Contents

1	Key and Criteria to the Selection of an Expression Platform	1
	GERD GELLISSEN, ALEXANDER W.M. STRASSER, and MANFRED SUCKOW	
2	<i>Escherichia coli</i>	7
	JOSEF ALTENBUCHNER and RALF MATTES	
2.1	Introduction	8
2.2	Strains, Genome, and Cultivation	9
2.3	Expression Vectors	11
2.3.1	Replication of pMB1-derived Vectors	11
2.3.2	Plasmid Partitioning	11
2.3.3	Genome Engineering	13
2.3.4	<i>E. coli</i> Promoters	14
2.4	Regulation of Gene Expression	15
2.4.1	Negative Control	16
2.4.2	Positive Control	18
2.4.2.1	l-Arabinose Operon	18
2.4.2.2	l-Rhamnose Operon	19
2.5	Transcription and Translation	21
2.5.1	Translation Initiation	21
2.5.2	Codon Usage	22
2.5.3	Translation Termination	26
2.5.4	Transcription Termination and mRNA Stability	26
2.6	Protein Production	27
2.6.1	Inclusion Body Formation	27
2.6.1.1	Chaperones as Facilitators of Folding	28
2.6.1.2	Fusion Protein Technology	29
2.6.2	Methionine Processing	29
2.6.3	Secretion into the Periplasm	30
2.6.4	Disulfide Bond Formation and Folding	31
2.6.5	Twin Arginine Translocation (TAT) of Folded Proteins	31
2.6.6	Disulfide Bond Formation in the Cytoplasm	32
2.6.7	Cell Surface Display and Secretion across the Outer Membrane	33
2.7	Examples of Products and Processes	34

2.8	Conclusions and Future Perspectives	35
	Appendix	36
	References	37
3	<i>Pseudomonas fluorescens</i>	45
	LAWRENCE C. CHEW, TOM M. RAMSEIER, DIANE M. RETALLACK, JANE C. SCHNEIDER, CHARLES H. SQUIRES, and HENRY W. TALBOT	
3.1	Introduction	45
3.2	Biology of <i>Pseudomonas fluorescens</i>	47
3.3	History and Taxonomy of <i>Pseudomonas fluorescens</i> Strain Biovar I MB101	47
3.4	Cultivation	48
3.5	Genomics and Functional Genomics of <i>P. fluorescens</i> Strain MB101	49
3.6	Core Expression Platform for Heterologous Proteins	52
3.6.1	Antibiotic-free Plasmids using <i>pyrF</i> and <i>proC</i>	52
3.6.2	Gene Deletion Strategy and Re-usable Markers	53
3.6.3	Periplasmic Secretion and Use of Transposomes	54
3.6.4	Alternative Expression Systems: Anthranilate and Benzoate-inducible Promoters	54
3.7	Production of Heterologous Proteins in <i>P. fluorescens</i>	55
3.7.1	Pharmaceutical Proteins	55
3.7.2	Industrial Enzymes	59
3.7.3	Agricultural Proteins	60
3.8	Conclusions	60
	Appendix	61
	References	62
4	<i>Staphylococcus carnosus</i> and other Gram-positive Bacteria	67
	ROLAND FREUDL	
4.1	Introduction	67
4.2	Major Protein Export Routes in Gram-positive Bacteria	68
4.2.1	The General Secretion (Sec) Pathway	69
4.2.2	The Twin-Arginine Translocation (Tat) Pathway	71
4.2.3	Secretion Signals	72
4.3	Extracytosolic Protein Folding	73
4.4	The Cell Wall as a Barrier for the Secretion of Heterologous Proteins	75
4.5	Degradation of Exported Proteins by Cell-associated and Secreted Proteases	75
4.6	<i>Staphylococcus carnosus</i>	76
4.6.1	General Description	76
4.6.2	Microbiological and Molecular Biological Tools	77
4.6.3	<i>S. carnosus</i> as Host Organism for the Analysis of Staphylococcal-related Pathogenicity Aspects	77
4.6.4	Secretory Production of Heterologous Proteins by <i>S. carnosus</i>	78

- 4.6.4.1 The *Staphylococcus hyicus* Lipase: Secretory Signals and Heterologous Expression in *S. carnosus* 78
- 4.6.4.2 Use of the Pre-pro-part of the *S. hyicus* Lipase for the Secretion of Heterologous Proteins in *S. carnosus* 80
- 4.6.4.3 Process Development for the Secretory Production of a Human Calcitonin Precursor Fusion Protein by *S. carnosus* 81
- 4.6.5 Surface Display on *S. carnosus* 82
 - Appendix 83
 - References 84

- 5 *Arxula adeninivorans* 89**
 - ERIK BÖER, GERD GELLISSSEN, and GOTTHARD KUNZE
 - 5.1 History of *A. adeninivorans* Research 89
 - 5.2 Physiology and Temperature-dependent Dimorphism 91
 - 5.3 Genetics and Molecular Biology 96
 - 5.4 *Arxula adeninivorans* as a Gene Donor 97
 - 5.5 The *A. adeninivorans*-based Platform 99
 - 5.5.1 Transformation System 99
 - 5.5.2 Heterologous Gene Expression 99
 - 5.6 Conclusions and Perspectives 105
 - Acknowledgments 105
 - Appendix 105
 - References 108

- 6 *Hansenula polymorpha* 111**
 - HYUN AH KANG and GERD GELLISSSEN
 - 6.1 History, Phylogenetic Position, Basic Genetics and Biochemistry of *H. polymorpha* 112
 - 6.2 Characteristics of the *H. polymorpha* Genome 115
 - 6.3 N-linked glycosylation in *H. polymorpha* 118
 - 6.4 The *H. polymorpha*-based Expression Platform 120
 - 6.4.1 Transformation 120
 - 6.4.2 Strains 122
 - 6.4.3 Plasmids and Available Elements 124
 - 6.5 Product and Process Examples 127
 - 6.6 Future Directions and Conclusion 129
 - 6.6.1 Limitations of the *H. polymorpha*-based Expression Platform 129
 - 6.6.2 Impact of Functional Genomics on Development of the *H. polymorpha* RB11-based Expression Platform 130
 - Appendix 132
 - References 136

- 7 *Pichia pastoris* 143**
 - CHRISTINE ILGEN, JOAN LIN-CEREGHINO, and JAMES M. CREGG
 - 7.1 Introduction 143

7.2	Construction of Expression Strains	144
7.2.1	Expression Vector Components	145
7.2.2	Alternative Promoters	146
7.2.3	Selectable Markers	147
7.2.4	Host Strains	148
7.2.4.1	Methanol Utilization Phenotype	148
7.2.4.2	Protease-deficient Host Strains	149
7.2.5	Construction of Expression Strains	149
7.2.6	Multicopy Strains	150
7.2.7	Growth in Fermentor Cultures	151
7.3	Post-translational Modification of Secreted Proteins	152
7.3.1	Secretion Signals	152
7.3.2	O-linked Glycosylation	153
7.3.3	N-linked Glycosylation	154
7.3.4	“Humanization” of N-linked Carbohydrate	156
7.4	Conclusions	157
	Acknowledgments	157
	Appendix	158
	References	160
8	<i>Yarrowia lipolytica</i>	163
	CATHERINE MADZAK, JEAN-MARC NICAUD, and CLAUDE GAILLARDIN	
8.1	History, Phylogenetic Position, Basic Genetics, and Biochemistry	163
8.1.1	Main Characteristics	163
8.1.2	Historical Perspective on the Development of Studies	164
8.1.3	Secretion of Proteins	165
8.1.4	Production of Heterologous Proteins and Glycosylation	166
8.2	Characteristics of the <i>Y. lipolytica</i> Genome	167
8.3	Description of the Expression Platform	168
8.3.1	Host Strains	168
8.3.2	Selection Markers and Expression Signals	170
8.3.2.1	Selection Markers	170
8.3.2.2	The Expression Cassette	172
8.3.2.2.1	Promoters	172
8.3.2.2.2	Secretion Targeting Signals	175
8.3.3	Shuttle Vectors for Heterologous Protein Expression	176
8.3.3.1	Replicative Vectors	176
8.3.3.2	Integrative Vectors	176
8.3.3.2.1	Examples of Mono-copy Integrative Vectors	177
8.3.3.2.2	Homologous Multiple Integrations	178
8.3.3.2.3	Non-homologous Multiple Integrations	179
8.3.3.2.4	Examples of Multicopy Integrative Vectors	179
8.3.3.2.5	Auto-cloning Vectors	179
8.4	Examples	181
8.5	Transformation Methods	182

8.5.1	Materials	182
8.5.2	Preparation of Competent Cells	182
8.5.3	Transformation	183
8.6	Conclusions and Future Trends	183
	Acknowledgments	184
	Appendix	184
	References	185
9	<i>Aspergillus sojae</i>	191
	MARGREET HEERIKHUISEN, CEES VAN DEN HONDEL, and PETER PUNT	
9.1	Introduction	191
9.2	Taxonomy	193
9.3	The Expression Platform	194
9.3.1	Strain Selection	194
9.3.2	Transformation	195
9.3.2.1	Protoplasting	195
9.3.2.2	Dominant Selection Markers	196
9.3.2.3	Auxotrophic Selection Markers	196
9.3.2.4	Re-usable Selection Marker	197
9.3.3	Promoter Elements	197
9.4	<i>Aspergillus sojae</i> as a Cell Factory for Foreign Proteins	199
9.4.1	Production of Fungal Proteins	200
9.4.2	Production of Non-fungal Proteins	201
9.4.3	Controlled Fermentation	202
9.5	Strain Development	203
9.5.1	Protease-deficient Strains	203
9.5.1.1	Ultra-violet (UV) Mutagenesis	203
9.5.1.2	Gene Disruption	204
9.5.1.3	Controlled Batch Fermentations	205
9.5.2	Low-viscosity Mutants	206
9.5.2.1	Gene Disruption	206
9.5.2.2	Controlled Fermentations	207
9.6	Outlook	209
	Acknowledgments	209
	Appendix	210
	References	212
10	<i>Sordaria macrospora</i>	215
	ULRICH KÜCK and STEFANIE PÖGGELER	
10.1	Introduction	215
10.2	General Biology	216
10.3	Morphological Characterization, Molecular Phylogeny and Life Cycle of <i>Sordaria macrospora</i>	216
10.4	Generation of Sterile Mutants as Host Strains	217
10.5	<i>S. macrospora</i> as a Safe Host for Heterologous Gene Expression	218

10.6	Molecular Genetic Techniques Developed for <i>S. macrospora</i>	219
10.7	Isolation and Characterization of Strong Promoter Sequences from <i>S. macrospora</i>	221
10.8	Construction of Vectors for Efficient Gene Expression in <i>S. macrospora</i>	222
10.9	Successful Expression of the Recombinant EGFP Reporter Gene in <i>S. macrospora</i>	225
10.10	Conclusions	227
	Acknowledgments	228
	Appendix	229
	References	230
11	Mammalian Cells	233
	VOLKER SANDIG, THOMAS ROSE, KARSTEN WINKLER, and RENE BRECHT	
11.1	Why Use Mammalian Cells for Heterologous Gene Expression?	233
11.2	Mammalian Cell Lines for Protein Production	234
11.3	Mammalian Expression Systems	235
11.3.1	Design of the Basic Expression Unit	235
11.3.2	Transient Expression and Episomal Vectors: Alternatives to Stable Integration	236
11.3.3	“Stable” Integration into the Host Genome	237
11.3.4	Selection Strategies for Mammalian Cells	239
11.3.5	Auxotrophic Selection Markers and Gene Amplification	241
11.3.6	The Integration Locus: a Major Determinant of Expression Level	242
11.4	Mammalian Cell-based Fermentation Processes	245
11.4.1	Batch and Fed-batch Fermentation	245
11.4.2	Continuous Perfusion Fermentation	246
11.4.3	Continuous Production with Hollow-fiber Bioreactors	248
11.5	Conclusions	249
	Acknowledgments	250
	Appendix	250
	References	251
12	Plant Cells	253
	RAINER FISCHER, RICHARD M TWYMAN, JÜRGEN DROSSARD, STEPHAN HELLWIG and STEFAN SCHILLBERG	
12.1	General Biology of Plant Cells	253
12.1.1	Advantages of Plant Cells for the Production of Recombinant Proteins	253
12.1.2	N-Glycan Synthesis in Plants	254
12.2	Description of the Expression Platform	255
12.2.1	Culture Systems and Expression Hosts	255
12.2.2	Derivation of Suspension Cells	255
12.2.3	Optimizing Protein Accumulation and Recovery	256
12.2.4	Expression Construct Design	256

12.2.5	Foreign Protein Stability	258
12.2.6	Medium Additives that Enhance Protein Accumulation	259
12.2.6.1	Simple Inorganic Compounds	259
12.2.6.2	Amino Acids	259
12.2.6.3	Dimethylsulfoxide	260
12.2.6.4	Organic Polymers	260
12.2.6.5	Proteins	260
12.2.7	Other Properties of the Culture Medium	261
12.2.8	Culture and Harvest Processes	261
12.3	Examples of Recombinant Proteins Produced in Plant Cell Suspension Cultures	263
12.4	Methodology Using Model Tobacco Cell Suspension Lines to Produce Recombinant Antibodies	263
12.5	Conclusions	267
	Appendix	268
	References	269
13	Wide-Range Integrative Expression Vectors for Fungi, based on Ribosomal DNA Elements	273
	JENS KLABUNDE, GOTTHARD KUNZE, GERD GELLISSSEN, and CORNELIS P. HOLLENBERG	
13.1	Why is a Wide-range Expression Vector Needed?	274
13.2	Which Elements are Essential for a Wide-range Expression Vector?	275
13.3	Structure of the Ribosomal DNA and its Utility as an Integration Target	275
13.3.1	Organization of the rDNA in Yeast	276
13.3.2	Sequence Characteristics of rDNA	277
13.4	Transformation Based on rDNA Integration	277
13.5	rDNA Integration as a Tool for Targeting Multiple Expression Cassettes	282
13.5.1	Co-integration of Reporter Plasmids in <i>A. adeninivorans</i>	282
13.5.2	Approaches to the Production of Pharmaceuticals by Co-integration of Different Genes	282
13.6	Conclusions and Perspectives	283
	Acknowledgments	284
	References	284
14	Comparative Fermentation	287
	STEPHAN HELIWIG, CHRISTOPH STÖCKMANN, GERD GELLISSSEN, and JOCHEN BÜCHS	
14.1	Introduction	288
14.2	<i>Escherichia coli</i>	289
14.2.1	Media and Fermentation Strategies	289
14.2.2	Downstream Processing	291

14.2.3	Case Study: Production of GFP in a Medium Cell Density Fermentation of <i>E. coli</i>	292
14.3	<i>Staphylococcus carnosus</i>	292
14.3.1	Media and Fermentation Strategies	293
14.4	<i>Arxula adeninivorans</i>	294
14.4.1	Current Status of Media and Fermentation Strategies	295
14.4.2	Development of Media and Fermentation Strategies	295
14.4.3	Case Study: Production of Heterologous Phytase in Shake-flask Cultures and a High-cell- density, Fed-batch Fermentation of <i>A. adeninivorans</i>	298
14.5	<i>Hansenula polymorpha</i>	298
14.5.1	Media and Fermentation Strategies	299
14.5.2	Downstream Processing	301
14.5.3	Case Study: Production of a Secreted Protein in <i>H. polymorpha</i>	301
14.6	<i>Sordaria macrospora</i>	301
14.6.1	Current Status of Media and Fermentation Strategies	303
14.6.2	Development of Media and Strategies for Submerged Cultivation	304
	Appendix	306
A14.1	<i>Escherichia coli</i> Media	306
A14.2	<i>Staphylococcus carnosus</i> Media	308
A14.3	Yeast Media	309
A14.4	<i>Sordaria macrospora</i> Media	312
	References	313
15	Recombinant Hepatitis B Vaccines: Disease Characterization and Vaccine Production	319
	PASCALE BROCKE, STEPHAN SCHAEFER, KARL MELBER, VOLKER JENZELEWSKI, FRANK MÜLLER, ULRIKE DAHLEMS, OLIVER BARTELEN, KYUNG-NAM PARK, ZBIGNIEW A. JANOWICZ, and GERD GELLISSEN	
15.1	Introduction	319
15.2	Virus and Disease Characteristics	320
15.2.1	The Hepadnaviruses	320
15.2.2	Subtypes of HBV	326
15.2.3	Pathogenesis	328
15.2.4	Immune Response	329
15.2.5	Prophylactic HBV Vaccines	331
15.3	Recombinant Vaccine Production	331
15.3.1	Yeasts as Production Organisms	331
15.3.2	Construction of a <i>H. polymorpha</i> Strain Expressing the Hepatitis B S-antigen	333
15.3.2.1	Expression Cassette and Vector Construction	333
15.3.2.2	Transformation of <i>H. polymorpha</i>	333
15.3.2.3	Strain Characterization	333
15.3.3	<i>H. polymorpha</i> -derived HBsAg Production Process	335
15.3.3.1	Fermentation (Upstream Process)	335
15.3.3.2	Purification (Downstream Processing)	337

15.4	HepavaxGene®	339
15.4.1	Preclinical Studies	339
15.4.2	Clinical Studies	340
15.4.3	Second-generation Prophylactic Vaccine@ SUPERVAX	342
15.5	Hepatitis B Vaccines: Past, Present, and Future	342
15.5.1	Use and Success of Prophylactic Hepatitis B Vaccination	342
15.5.2	Current Shortcomings of Hepatitis B Vaccines	342
15.5.2.1	Non-responders	343
15.5.2.2	Incomplete Vaccination	343
15.5.2.3	Escape Variants	343
15.5.3	Alternative Vaccine Strategies	344
15.5.3.1	Oral Administration of Plant-derived, Edible Vaccines	344
15.5.3.2	Oral Administration of Live Bacterial Vectors	345
15.5.3.3	Live Viral Vectors	345
15.5.3.4	DNA Vaccines	345
15.5.3.5	Single-dose Vaccines	345
15.5.3.6	Mammalian Cell-derived, PreS1/preS2-containing Vaccines	346
15.5.3.7	Novel Adjuvants	346
15.5.4	Treatment of Chronic Hepatitis	346
15.5.5	Combination Vaccines	347
15.6	Conclusions	348
	References	348
16	Biopharmaceuticals and the Industrial Environment	361
	GEORG MELMER	
16.1	Introduction	361
16.2	Early Success Stories	363
16.3	The Bumpy Road Appeared	365
16.4	The Breakthrough in Many Areas	366
16.5	Which are the Current and Future Markets?	374
16.6	The Clinical Development of Biopharmaceuticals	376
16.7	Drug Delivery and Modification of Proteins	378
16.8	Expression Systems for Commercial Drug Manufacture	380
16.9	Will Demand Rise?	380
16.10	Conclusions and Perspectives	381
	References	383
	Subject Index	385